Product Description
Mechanisms of Action: 5-HT1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Korea
Approved Indications: None
Known Adverse Events: None
Company: CSPC
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Schizophrenia|Hypertension|Alzheimer Disease|Generalized anxiety disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2300075407 | N/A |
Not yet recruiting |
Depressive Disorder |
2025-12-31 |
|
| ChiCTR2300077056 | N/A |
Recruiting |
Generalized anxiety disorder |
2025-08-31 |
|
| CTR20212763 | N/A |
Completed |
Peptic Ulcer|Hypertension |
2022-01-24 |
|
| ETAPE | N/A |
Not yet recruiting |
Hypertension |
2021-11-02 |